Article
Docetaxel (Taxotere) has been approved by the FDA for the treatment of hormone-refractory metastatic prostate cancer when used in combination with prednisone.
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy